Integra LifeSciences adopts change in control severance program for executives
Integra LifeSciences adopted a change in control severance program on December 12, 2024, covering four executive officers and CFO Lea Knight. The program takes effect January 1, 2025, and pays severance only after a qualifying termination within two years of a change in control that occurs by December 31, 2025.
Key points
- Program effective January 1, 2025, renewing a program that was scheduled to expire December 31, 2024
- Lump sum severance of 1.5 times salary and target bonus, or 2 times for CFO Lea Knight
- Includes COBRA premium support for up to 18 months and outplacement services for up to 12 months
- Payments are conditioned on a general release of claims and may be reduced under a best pay cap for excise tax purposes
The filing
Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 6:59 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on December 17, 2024.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.